PCN30 USING THE DIFFERENCE IN DIFFERENCE METHOD TO UNDERSTAND OUTCOMES IN PROSTATE CANCER  by Lee, WC et al.
255Abstracts
a variety of interpretations. The objectives of this paper are to
critically evaluate the alternatives and present a set of statistics
with known psychometric properties and unambiguous inter-
pretation. METHODS: Data from several cancer registries 
and retrospective studies were mined to identify and categorize
the various naturally-occurring scenarios impacting ARDI.
RESULTS: Three statistics were derived from these samples,
which discriminate among three key ARDI aspects, labeled
“planned ARDI”, “delivered ARDI” and “% Optimal Dose”.
They measure, respectively, the physician’s prescribed dose inten-
sity, the actual delivered dose intensity, and the total delivered
dose independent of time, all relative to the associated standard.
Several visualization and analysis techniques are also presented
that employ these measures to determine the relative contribu-
tion of the various fundamental causes of suboptimal dose
administration. These causes include cycle delay, dose reduction,
treatment attenuation and planned deviation. CONCLUSIONS:
The methods presented provide those engaged in naturalistic
research and clinical performance improvement with a validated
set of statistics and a concise, unambiguous terminology to
measure and interpret the complex treatments involved in the
study of chemotherapy effectiveness.
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OBJECTIVES: The “difference in difference” method (DD) is
commonly used in health policy-oriented research. However, it
is seldom used to design and analyze cohort outcomes studies.
We applied the DD method to assess an independent association
between androgen deprivation therapy (ADT) and bone compli-
cations among non-metastatic prostate cancer patients receiving
ADT. METHODS: Using medical claims data from a 5%
national random sample of Medicare beneﬁciaries, prostate
cancer patients who initiated ADT in 1992–94 without bone
metastasis at baseline were identiﬁed (the “ADT” group, N =
3887). Prostate cancer patients without ADT matched on a 1 :2
ratio on the basis of age, race and Charlson comorbidity index
constituted the “comparison” group (N = 7774), a group similar
to the ADT group but unaffected by ADT. We analyzed seven
subsequent years of inpatient, outpatient, and physician claims
data to identify rates of bone complications (e.g., fractures,
osteoporosis/osteopenia) conditional on patient survival.
RESULTS: Fracture incidence rates for the initial baseline two
years and 7 years respectively (conditional on survival) were
11.3% and 83.3% for the ADT group versus 10.4% and 56.3%
for the comparison group. As the temporal effect from the com-
parison group may reﬂect change that would have occurred in
the absence of ADT over time due to aging and disease pro-
gression, we subtracted the change (56.3% – 10.4%) for the
comparison group from the corresponding change (83.3% –
11.3%) for the treatment group, in an effort to account for the
unmeasured time effects. Thus, the difference in difference (DD)
estimate, 26-percentage point change (72% – 45.9%), reﬂects
the association of ADT with fracture. CONCLUSION: This esti-
mate will be valid if the time varying factors (e.g., disease pro-
gression) are consistent or equivalent in treatment and
comparison groups. Future research using clinically detailed data
should assess whether such time-varying factors are different
between those undergoing ADT and those not.
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OBJECTIVES: Methods from the traditional survival analysis
are not directly applicable to estimate medical costs since
patients accumulate costs with different rate functions over time,
leading to negatively biased estimates. A number of authors have
incorporated inverse probability weightiness (IPW) technique to
correct for this bias. None of these authors, however, compare
their result with the method, which supposedly yields bias esti-
mates, i.e. OLS over uncensored observations. In this paper, we
test the differences between the coefﬁcient estimates of OLS over
uncensored observations and that of proposed model to deter-
mine whether using weight yields statistically different results.
Moreover, we compare the estimation power of the proposed
alternative models. METHODS: A Hausman kind of test is pro-
posed to compare the weighted estimator and unweighted esti-
mators. Predictive Power tests are used to choose between
alternative models. RESULTS: Our data set consists of an incep-
tion cohort of 773 patients with incident cases of prostate, colon,
lung and breast cancer from 24 Michigan community hospitals
and their afﬁliated oncology units between the years 1994–1997.
Hausman test indicated the results are statistically different. Pre-
dictive Power tests yield that Lin [2003] model is better than
Lin[2000], Carrides et al. [2000] and Bang and Tsiatis [2000].
CONCLUSION: Two conclusions are as follows: 1. If the error
terms are homoskedastic and we fail to reject Hausman test use
unweighted simple OLS over complete observations. 2. Other-
wise, weighted estimators yield consistent results and predictive
power tests can be used to choose among them.
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OBJECTIVES: To propose a method to estimate total medical
cost from censored data. METHODS: In this paper, the inverse
probability of weighted (IPW) least squares method is used to
assess the effect of covariates (e.g. patient and clinical charac-
teristics) on medical cost with censored data. We outlined IPW
least squares as applied to censored medical cost data, including
the statistical properties of the estimation, then introduced
Hausman type of test to compare the estimators calculated by
using IPW least squares and OLS over uncensored data and
applied our method to the estimation of cancer costs RESULTS:
Medicare claim ﬁles are examined to apply our method. Each
patient is followed two years after diagnosis of cancer (breast,
colon, prostate or lung). For patients who have less than two
years of cost and still alive at the end of the study were consid-
ered censored. The reference group fro treatment modalities is
surgery plus adjuvant therapies, the reference group for site of
cancer is lung. Variables that reach statistical signiﬁcance (p <
0.05) include physical function, type of cancer (except colon),
surgery and radiation, radiation only, and chemotherapy and
radiation. Ten additional points in patient’s prior physical func-
tion score decreases total medical cost by 0.7 percent. Prostate
cancer patients and breast cancer patients cost 1.36 and 2.46
times lower than lung cancer patients respectively, these esti-
mates are 1.16 times and 2.40 times according to IPW least
square estimation. CONCLUSIONS: Hausman test suggests that
IPW estimates are signiﬁcantly different (p < 0.05) and suggested
